Theravance director granted shares and options

Theravance Biopharma director Susannah Gray received equity compensation in the form of shares and options.

Rhea-AI Filing Summary

Theravance Biopharma director Susannah Gray received equity compensation in the form of shares and options. On June 12, 2026, she was granted 6,009 Ordinary Shares, bringing her direct holdings to 48,146 Ordinary Shares after the award.

On the same date, she also received a share option for 13,398 Ordinary Shares at an exercise price of $16.64 per share, expiring on June 11, 2036. According to the vesting terms, 1/12 of the option vests after each completed month of continuous service following the grant date, and any remaining unvested portion vests on the date of the next annual shareholder meeting if she remains in continuous service.

Insider Trade Summary

Grant/Award: 19,407 shares

Grant/Award 2 txns

Insider GRAY SUSANNAH

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	13,398	$0.00	$0.00
Grant/Award	Ordinary Shares	6,009	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 13,398 contracts (Direct); Ordinary Shares — 48,146 shares (Direct)

Footnotes (1)

1. F1. This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

Key Figures

Ordinary Shares granted: 6,009 shares Shares held after grant: 48,146 shares Option grant size: 13,398 shares +3 more

6 metrics

Ordinary Shares granted 6,009 shares Equity award on June 12, 2026

Shares held after grant 48,146 shares Direct Ordinary Share holdings post-award

Option grant size 13,398 shares Share Option (Right to Buy) underlying Ordinary Shares

Option exercise price $16.64 per share Conversion/exercise price of option

Option expiration June 11, 2036 Expiration date of share option

Monthly vesting fraction 1/12 of option Vests after each completed month of continuous service

Key Terms

Share Option (Right to Buy), Grant, award, or other acquisition, Ordinary Shares, exercise price, +1 more

5 terms

Share Option (Right to Buy) financial

"Share Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Ordinary Shares financial

"security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

exercise price financial

"conversion_or_exercise_price: 16.6400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

continuous service financial

"provided the optionee remains in continuous service on such date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Theravance Biopharma (TBPH) director Susannah Gray receive in this Form 4 filing?

Director Susannah Gray received 6,009 Ordinary Shares and a share option for 13,398 Ordinary Shares. These awards are classified as a grant or award acquisition and represent equity-based compensation rather than open-market buying or selling of TBPH stock.

How many Theravance Biopharma (TBPH) shares does Susannah Gray hold after the award?

After the grant, Susannah Gray holds 48,146 Ordinary Shares directly. This figure reflects her direct ownership following the issuance of 6,009 new Ordinary Shares reported in the Form 4, providing context for the scale of the compensation award.

What are the key terms of the share option granted to Susannah Gray by Theravance Biopharma (TBPH)?

Gray received a share option covering 13,398 Ordinary Shares with an exercise price of $16.64 per share, expiring on June 11, 2036. The option is a right to buy TBPH Ordinary Shares if and when it becomes vested and exercised.

How does the Theravance Biopharma (TBPH) option granted to Susannah Gray vest over time?

The option vests as to 1/12 of the shares after each completed month of continuous service following the grant date. Any remaining unvested shares then vest on the date of the next annual shareholder meeting, provided she remains in continuous service with the company.

Is Susannah Gray’s Theravance Biopharma (TBPH) Form 4 transaction an open-market purchase or sale?

No. The Form 4 classifies both transactions with code A, meaning grant, award, or other acquisition. They represent compensation awards of shares and options, not open-market purchases or sales, and therefore do not reflect discretionary trading activity in TBPH shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 09:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRAY SUSANNAH

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/12/2026		A		6,009	A	$0	48,146	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$16.64	06/12/2026		A		13,398		(1)	06/11/2036	Ordinary Shares	13,398	$0	13,398	D

Explanation of Responses:

1. This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

	/s/ Brett A. Grimaud, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)